GLYCOPYRROLATE MSDS PDF

  • June 30, 2019

SAFETY DATA SHEET. PRODUCT: Glycopyrrolate Injection USP. Section 1: PRODUCT AND COMPANY INFORMATION. 54/1, Boodhihal village,. Nelamangala. Glycopyrrolate. 1-Methylpyrrolidyl alpha-phenylcyclopentaneglycolate methobromide;. Glycopyrrolate bromide; Glycopyrronium bromide. Glycopyrronium (as the bromide salt glycopyrrolate) is a synthetic anticholinergic agent In October , glycopyrrolate was approved by the FDA for use as a FDA label. Download ( KB). MSDS. Download ( KB).

Author: Fera Tygoramar
Country: Brunei Darussalam
Language: English (Spanish)
Genre: Video
Published (Last): 26 August 2017
Pages: 289
PDF File Size: 6.67 Mb
ePub File Size: 2.57 Mb
ISBN: 698-5-47290-111-7
Downloads: 64227
Price: Free* [*Free Regsitration Required]
Uploader: Ker

Venlafaxine The risk or severity of Tachycardia can be increased when Venlafaxine is combined with Glycopyrronium. The risk or severity of adverse effects can be increased when Hexocyclium is combined with Glycopyrronium. The risk or severity of adverse effects can be increased when Oxitropium is combined with Glycopyrronium.

The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with 4-Bromo-2,5-dimethoxyamphetamine.

Sodium sulfate The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Glycopyrronium. Poldine The risk or severity of adverse effects can be increased when Poldine is combined with Glycopyrronium. Cisplatin The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Cisplatin.

Cirazoline The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Cirazoline. Bupropion Glycopyrronium may increase the anticholinergic activities of Bupropion. The therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Glycopyrronium.

Glycopyrronium

DrugBank does not sell nor buy drugs. The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Bambuterol. Mirabegron The risk or severity of urinary retention can be increased when Glycopyrronium is combined with Mirabegron. The risk or severity of adverse effects can be increased when Biperiden is combined with Glycopyrronium. Mazaticol The risk or severity of adverse effects can be increased when Mazaticol is combined with Glycopyrronium.

  FRED SABERHAGEN BOOK OF SWORDS PDF

Galantamine The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Galantamine.

Glycopyrronium – DrugBank

Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Glycopyrronium. The risk or severity of adverse effects can be increased when Mebeverine is combined with Glycopyrronium.

The risk or glycopyrro,ate of adverse effects can be increased when Cycrimine is combined with Glycopyrronium.

Cilostazol The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Cilostazol. Moxonidine The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Moxonidine. Chlorprothixene The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Glycopyrronium.

The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Ephedrine. The therapeutic efficacy of Lactic Acid can be decreased when used in combination with Glycopyrronium. Sodium iodide The therapeutic efficacy of Sodium iodide can be decreased when used in combination with Glycopyrronium. Olodaterol The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Olodaterol. The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Glycopyrronium.

The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Arbutamine. The risk or severity of Tachycardia can be increased when Metaraminol is combined with Glycopyrronium.

The risk or severity of Tachycardia can be increased when Bitolterol is combined with Glycopyrronium. Diphenidol The risk or severity of adverse effects can be increased when Diphenidol is combined with Glycopyrronium. General Function Receptor activity Specific Function The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Diamorphine.

  ADMINISTRACION DE RECURSOS HUMANOS WERTHER Y DAVIS PDF

The therapeutic efficacy of Emodin can be decreased when used in combination with Glycopyrronium. The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Mephedrone.

The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Glycopyrronium. Rocuronium The risk or severity of adverse effects can be increased when Rocuronium is combined with Glycopyrronium. Framycetin The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Framycetin. General Function G-protein coupled acetylcholine receptor activity Specific Function The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Ginkgo biloba.

The risk or severity of adverse effects can be increased when Paroxetine is combined with Glycopyrronium. The serum concentration of Benzthiazide can be increased when it is combined with Glycopyrronium. The risk or severity of adverse effects can be increased when Pirenzepine is combined with Glycopyrronium. U Muscarinic acetylcholine receptor M3.